IndiCell - Individualized pluripotent stem cell-based therapy
|Coordinator||Lunds universitet - Lunds universitet Biomedicinskt Centrum|
|Funding from Vinnova||SEK 39 999 932|
|Project duration||October 2021 - September 2026|
|Venture||Innovation milieus in precision health|
|Call||Innovation milieus in precision Health 2021|
Purpose and goal
There are three main aims of IndiCell: 1)Develop iPS cell-based therapy for two model project, Parkinson’s disease and Macular degeneration 2)Create a development pipeline for iPS cell therapies that includes state-of-the-art workflows addressing generic processes, competence and quality controls 3)Become an important global actor within stem cell therapies
Expected results and effects
Development of precision medicine with iPS cell therapy for Parkinson’s disease and Macula degeneration. Increase the speed and number of translations of stem cell therapies from pre-clinical transplantations to patients and identify innovation potential in techniques, processes, devices and knowledge. Put Sweden on the global map of stem cell therapies. Increase the awareness of stem cell therapies among the public.
Planned approach and implementation
IndiCell will be executed by implementation of 6 workpackage where 4 will address the process from donation of cells for reprogramming, enter into a specialized GMP facility via production of iPS cells, therapeutic cells, sorting of cells, quality testing of cellular products and then exit of cells from GMP to bedside and local washing and preparation of cells for transplantation to the patient. 2 work packages which deal with monitoring, defining and creating innovations and one dealing with the project management and actively prepare for the future after the Vinnova funding.